BTIG analyst Ryan Zimmerman maintains a Neutral rating on Medtronic after CMS proposes national coverage for renal denervation in uncontrolled hypertension. The news, while expected, is a win for Medtronic, who has been preparing sites for coverage with the launch of Symplicity Spyral. BTIG sees it as opening up a “massive” potential patient pool.

Read more at Yahoo Finance: CMS decision opens ‘massive’ patient pool for Medtronic, says BTIG